Transdermal delivery of phosphorodiamidate Morpholino oligomers across hairless mouse skin by Pannier, Angela K. et al.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Biological Systems Engineering: Papers and 
Publications Biological Systems Engineering 
5-2004 
Transdermal delivery of phosphorodiamidate Morpholino 
oligomers across hairless mouse skin 
Angela K. Pannier 
University of Nebraska-Lincoln, apannier2@unl.edu 
Vikram Arora 
AVI BioPharma, Corvallis, OR 
Patrick L. Iversen 
AVI BioPharma, Corvallis, OR 
Rhonda M. Brand 
Feinberg School of Medicine at Northwestern University, rhbrand@enh.org 
Follow this and additional works at: https://digitalcommons.unl.edu/biosysengfacpub 
 Part of the Biological Engineering Commons 
Pannier, Angela K.; Arora, Vikram; Iversen, Patrick L.; and Brand, Rhonda M., "Transdermal delivery of 
phosphorodiamidate Morpholino oligomers across hairless mouse skin" (2004). Biological Systems 
Engineering: Papers and Publications. 159. 
https://digitalcommons.unl.edu/biosysengfacpub/159 
This Article is brought to you for free and open access by the Biological Systems Engineering at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Biological Systems 
Engineering: Papers and Publications by an authorized administrator of DigitalCommons@University of Nebraska - 
Lincoln. 
1. Introduction
Antisense oligomers represent the ultimate in ra-
tional drug design, in that they have been devel-
oped to block the translation of a particular protein 
through specific interaction with its mRNA. Phos-
phorodiamidate Morpholino oligomers (PMOs) 
represent a neutral DNA analog chemistry, in that, 
they have a non-ionic phosphorodiamidate back-
bone combined with a morpholine ring replacing 
the deoxyribose sugar with the additional replace-
ment of one of the non-bridging oxygen atoms with 
a dimethylamine (Summerton and Weller, 1997). 
These modifications confer improved oligomer 
properties, including better hybrid duplex stability, 
little or no non-antisense activity, relatively good 
aqueous solubility, low production costs (Summer-
ton and Weller, 1997), resistance to nucleases (Hud-
ziak et al., 1996), high specificity and better efficacy 
than other types of antisense structural types (Stein 
et al., 1997). With their neutral chemistry, PMOs 
have the potential to be delivered passively, with 
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Abstract
The skin is the largest organ in the body and an obvious route for both local and systemic drug delivery. Anti-
sense oligomers have tremendous potential as therapeutic agents for numerous diseases. The objective of this 
study was to investigate the influence of vehicle on the transdermal delivery of several phosphorodiamidate 
Morpholino oligomers (PMOs) with different sizes, lengths, base compositions, sequences, and lipophilicities. 
Eleven different PMOs were synthesized complementary to biologically relevant gene targets and delivered 
across hairless mouse skin in vitro using vehicles composed of 95% propylene glycol, 5% linoleic acid (PG/LA), 
water, 50% water:50% PG/LA, and 75% water:25% PG/LA. The data suggest that size, sequence and guanine 
composition all influence transdermal penetration. There was an inverse linear relationship between size and 
penetration for a given sequence when the PG/LA formulation was used (r 2 = 0.94), but this trend was not ev-
ident when the vehicle contained water. An oligomer targeted to the gene p53 had lower than expected trans-
dermal penetration based on its size, but was shown to localize within the skin, demonstrating that sequence 
and thus target will impact transdermal delivery. The presence of G-quartets correlated with better PMO pen-
etration from a water vehicle. Overall, the data suggest that some oligomers and vehicles would be better for 
transdermal delivery and others for topical applications.
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chemical penetration enhancers such as water or 
propylene glycol.
Transdermally delivered oligomers with charged 
backbones have been demonstrated to cross the 
skin in vitro (Nolen et al., 1994; Brand and Iversen, 
1996; Brand et al., 1998a; Oldenberg et al., 1995). In 
vivo studies have shown that antisense oligomers 
can enter into target organs (Vlassov et al., 1993; 
Vlassov et al., 1994), and induce changes in target 
enzymes (Brand et al., 2001; Arora et al., 2002). The 
transdermal delivery of neutral PMOs using chem-
ical penetration enhancement techniques has yet to 
be investigated, though preliminary data has dem-
onstrated that the flux of a PMO targeted to cyto-
chrome P4503A2 in propylene glycol and linoleic 
acid was nearly 20 times greater than that reported 
with iontophoretic delivery of the same sequence 
with a phosphorothioate (PS) backbone (Brand and 
Iversen, 2000). Furthermore, in vivo topical appli-
cation led to inhibition of cytochrome P4503A2 lev-
els in rat liver and skin (Arora et al., 2002).
The objectives of this study are to investigate 
the transdermal delivery potential of several PMOs 
with different sizes, lengths, base compositions, se-
quences, and lipophilicities as well as to determine 
the effect of vehicle composition on the perme-
ation of these PMOs through hairless mouse skin. 
Eleven different PMOs were synthesized comple-
mentary to telomeric or biologically relevant gene 
targets and delivered across hairless mouse skin in 
vehicles composed of either 95% propylene glycol, 
5% linoleic acid, water, 50% water/50% solution 
of 95% propylene glycol, 5% linoleic acid, and 75% 
water/25% solution of 95% propylene glycol, 5% 
linoleic acid. The effect of vehicle combinations on 
oligomer penetration will be used to aid in the de-
sign of delivery systems for topical or systemic an-
tisense targets.
2. Material and methods
2.1. Synthesis of oligomers
The PMOs were synthesized at AVI BioPharma 
(Corvallis, OR) using a Gilson AMS422 Automated 
Peptide Synthesizer by solid phase synthesis (on a 
1% divinylbenzene crosslinked aminomethylpoly-
styrene resin) from activated Morpholino subunits, 
prepared from commercially available ribonucle-
osides. After synthesis completion, cleavage from 
resin, and ammonolytic removal of base protect-
ing groups, the trityl-on oligomers were purified by 
ion exchange (SAX) chromatography on a Bio-Rad 
EconoSystem low pressure chromatography sys-
tem. Following purification, a 6-carboxyfluorescein 
group was attached to the 5′-terminus of the oligo-
mer, which were then detritylated, desalted by re-
versed phase (RP) chromatography, and lyoph-
ilized to yield PMOs in powder form. Analysis of 
the PMOs was performed by HPLC (SAX and RP) 
and MALDI-TOF mass spectrometry. The PMOs 
were then reconstituted in either sterile water or 
propylene glycol.
2.2. Octanol/water partition coefficients
Two milliliters each of water and octanol were 
placed in glass test tubes, which were then capped 
and rocked overnight to allow for equilibration. 
Four hundred microliters of a 5 μM oligomer solu-
tion was then added to the octanol/water and the 
tube was rocked for 24 h (Carelli et al., 1992). At 
that time, the two phases were allowed to separate 
and the concentration of oligomer in each phase 
was determined fluorometrically, with a Turner 
Quantech fluorometer (Barnstead Thermolyne, 
Dubuque, IA).
2.3. Transdermal delivery
Female hairless mice (CRL: SKH1, Charles River 
Laboratories, Wilmington, MA) dorsal skin was 
freshly excised and placed into a modified Bro-
naugh diffusion chamber system (Permegear, 
Rieglesville, PA), where the temperature of the 
skin was maintained at 32 °C throughout the exper-
iment. The skin was equilibrated in buffer for 3 h 
before the beginning of each experiment. One hun-
dred microliters of PMOs, diluted to a final concen-
tration of 5 μM in either 95% propylene glycol, 5% 
linoleic acid (PG/LA), water, 50% water/50% PG/
LA or 75% water/25% PG/LA, were exposed to the 
epidermal side of the skin. The diffusion chamber’s 
receiver compartment was perfused with 25 mM 
HEPES, 133 mM NaCl at pH 7.4 at a flow rate of 
2.1 ml/h. Fractions of the effluent were collected in 
1 h intervals.
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2.4. Assay methods and data analysis
Oligomer flux was assayed by determining the flu-
orescence of each fraction with a Turner Quantech 
fluorometer (Barnstead Thermolyne, Dubuque, IA) 
set to 490/515 nm (excitation/emission). Because 
skin auto fluoresces at these wavelengths, back-
ground controls were performed with each of the 
vehicles (PG/LA, water, 50% water/50% PG/LA, 
or 75% water/25% PG/LA). The receiver solution 
fluorescence of the control skin was measured at 
each time point and then subtracted from those de-
termined after delivery of the fluorescently labeled 
oligomers, so that the differences in fluorescence 
were due to oligomer flux. This technique was ver-
ified by demonstrating that the transdermal ab-
sorption of a fluorescently labeled phosphorothio-
ate oligonucleotide targeted to a 6-base telomeric 
oligomer was the same as an 35S-labeled version of 
the same sequence (Brand and Iversen, 1996).
The slope of the linear portion of the cumulative 
transport versus time curve was taken as the steady-
state flux. Each oligomer was tested between three 
and eight times in each of either three or four vehi-
cles (95% propylene glycol, 5% linoleic acid (PG/
LA), water, 50% water/50% PG/LA or 75% wa-
ter/25% PG/LA). All values are expressed as mean 
flux ± s.e.m. The enhancement ratio for each com-
pound in each vehicle was determined by dividing 
the flux of a compound in a particular vehicle by its 
flux in propylene glycol. The mean penetration from 
PG/LA and water were added together to obtain a 
theoretical addition, which should be equivalent to 
the penetration from 50% PG/LA:50% water, if there 
are no synergistic or inhibitory effects. The error as-
sociated with this curve was determined by adding 
the variance of each mean and then finding the stan-
dard error from the new variance. Significant dif-
ferences were assessed via ANOVA followed by a 
Tukey post-test at the level of P < 0.05, using Graph-
Pad Prism (GraphPad Software, San Diego, CA).
2.5. Photomicrography
Representative skin samples were fixed for further 
analysis by fluorescent microscopy. Skin was re-
moved from the diffusion chamber, blotted dry, 
trimmed down so that regions of the skin not ex-
posed to the donor vehicle were cut away, and then 
placed in plastic molds filled with embedding me-
dium for frozen tissue processing (Sakura Finetek, 
Torrance, CA). The molds were then wrapped in alu-
minum foil to prevent exposure to light and frozen in 
a −80 °C freezer. Cryostat sections (5 μm) were cut at 
Oregon State University Veterinary Diagnostic Lab-
oratory (Corvallis, OR). Slides were air-dried in dark 
for 30 min and cover-slip mounted using Fluoro-
mount-G mounting medium (Southern Biotechnol-
ogy Associates, Birmingham, AL). A Nikon Diaphot 
300 microscope connected to an Olympus (Melville, 
NY) Magnafire SP-brand digital camera was used to 
take the photomicrographs. The exposure times for 
all fluorescent pictures were kept constant at 11 s.
3. Results
Eleven different PMOs were successfully synthe-
sized complementary to telomeric or biologically 
relevant gene targets. To determine the effect of size 
and sequence on passive transdermal delivery, the 
TAG and CTA oligomers were synthesized to vari-
ous lengths consisting of a base repeat unit with fi-
nal lengths of 6, 9, 12, 18 or 24 bases. The telomeric 
mimic sequence tested (5′-d(TTAGGG)-3′)n is de-
noted as TAG-N and its complements are termed 
CTA-N (5′-d(CCCTAA)-3′)n, where n corresponds 
to the number of repeat units in the TAG and corre-
sponding CTA oligomers, and n corresponds to the 
number of total bases, i.e. TAG-12 has 12 bases con-
sisting of two TTAGGG repeat sequences and CTA-
24 consists of 24 bases consisting of 4-CCCTAA 
repeat sequences. All of these lengths were synthe-
sized for both the TAG and CTA oligomers. The 
large numbers of guanines in the longer TAG mole-
cules resulted in very poor solubility in all solvents, 
leading to cessation of their use in this study. Four 
oligomers targeted to biologically active sites were 
synthesized, termed MYB, MYC-1, MYC-2 and P53. 
The MYC-1 and MYC-2 oligomers are both directed 
at the c-myc gene, but differ in their sequence and 
lipopholicity. These oligomers were used to reveal 
more broadly applicable information concerning 
size and sequence. Descriptors of each oligomer, in-
cluding name, sequence, length, molecular weight, 
percent guanine composition, and log octanol/wa-
ter coefficient are summarized in Table 1.
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PMO penetration across hairless mouse skin was 
first determined in PG/LA. For both the TAG and 
CTA molecules, flux was inversely proportional to 
size (r2=0.94 for both data sets) (Figure 1, Table 2) 
and overall CTA oligomers had greater flux than 
the TAG molecules, for all lengths tested (P<0.05). 
The biologically active oligomers all have similar 
size (20 or 24 bases long) and were also passively 
delivered in 95% propylene glycol/5% linoleic acid 
across hairless mouse skin (Table 2, Figure 2). There 
was some correlation between size and penetration, 
as evidenced by the similar transport of the two 24-
mers, MYB and CTA-24. The two MYC oligomers 
exhibited higher flux than would be expected based 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
on their size, and yet even with their different se-
quences and lipopholicities, they penetrated sim-
ilarly. The P53 oligomer, however, had lower flux 
than would be expected based on its size.
To examine the effect of vehicle on PMO deliv-
ery, penetration across hairless mouse skin was 
then determined in water, 50% water/50% PG/LA 
and for three representative oligomers, 75% wa-
ter/25% PG/LA. Mean steady-state flux, standard 
error, and number of replicates for each of the 11 
compounds in all vehicles, as well as the enhance-
ment ratio relative to the PG/LA solvent for each of 
the vehicles, are summarized in Table 2. There are 
a number of possible effects that altering the sol-
vents could have on the transdermal penetration of 
PMOs including no change in flux, flux inhibition 
or flux enhancement.
For the TAG molecules, the flux from the wa-
ter vehicle was 30% of that obtained with the PG/
LA vehicle (Table 2). The 50% water/50% PG/LA 
vehicle resulted in transport similar to that of just 
the PG/LA vehicle (P>0.05), and thus demonstrates 
that a vehicle with even 50% PG/LA enhances the 
penetration of the TAG molecules as well as a 100% 
PG/LA vehicle. TAG-12 was selected as a repre-
sentative molecule. Its transport from the 75% wa-
ter/25% PG/LA vehicle was found to be interme-
diate to that achieved with either just water or just 
PG/LA (Table 2).
A water vehicle severely inhibited the penetra-
tion of the CTA oligomers causing a steady-state 
Figure 1. Comparison of size (number of bases) and steady 
state flux across hairless mouse skin for telomeric com-
pounds in PG/LA (*, CTA; ■, TAG). Data is reported as 
mean flux ± S.E. (r 2 = 0.94 for both data sets).
Table 1. Summary of phosphorodiamidate Morpholino oligomers properties
Oligo name         Sequence                                                                         Lengtha            MWb                LogKowc               % Gd
TAG-6  5′_-TTA GGG-3′  6  2686.36  0.14  50
TAG-9  5′-TTA GGG TTA-3′  9  3686.21  0.55  33
TAG-12  5′-TTA GGG TTA GGG-3′  12  4752.1  1.20  50
CTA-6  5′-CCC TTA-3′  6  2566.28  0.68  0
CTA-12  5′-CCC TTA CCC TTA-3′  12  4511.95  0.46  0
CTA-18  5′-CCC TTA CCC TTA CCC TTA-3′  18  6457.62  0.10  0
CTA-24  5′-CCC TTA CCC TTA CCC TTA CCC TTA-3′  24  8403.28  –0.19  0
MYB  5′-TAT GCT GTG CCG GGG TCT TCG GGC-3′  24  8716.44  0.75  42
MYC-1  5′-ACG TTG AGG GGC ATC GTC GC-3′  20  7378.33  –0.39  40
MYC-2  5′-GCT AAC GTT GAG GGG CAT CG-3′  20  7402.36  0.02  40
P53  5′-CCC TGC TCC CCC CTG GCT CC-3′  20  7106.13  0.68  15
a. Oligomer length in terms of the number of bases.
b. Molecular weight (g/mol).
c. Log octanol/water partition coefficient.
d. Percent of guanine bases in oligomer (no. of G’s/total number of bases ×100).
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flux of less than 10% of that achieved with PG/LA 
for all four CTA oligomers (Table 2). The 50% wa-
ter/50% PG/LA vehicle resulted in transport inter-
mediate to that of water and PG/LA for the CTA 
oligomers, with the exception of CTA-18, whose 
transport in the 50% vehicle was nearly equivalent 
to its flux in the PG/LA vehicle.
The MYB oligomer delivered in either water or 
PG/LA had similar transport (P > 0.05). However, 
combining the two vehicles (50% water/50% PG/
LA), resulted in a synergistic effect, in which the 
transport of MYB from the combined vehicle was 
greater than the sum of the individual effects of the 
two vehicles (Table 2, Figure 3). For both of the MYC 
oligomers, use of a water vehicle resulted in trans-
port similar to that achieved with PG/LA (P > 0.05), 
but combining the two vehicles (50% water/50% 
PG/LA) for either MYC oligomer resulted in an ad-
ditive effect, that is the sum of the individual effects 
of the vehicles approximated the transport of the 
combination of vehicles (P > 0.05) (Table 2).
The P53 oligomer exhibited no transport across 
the skin in any vehicle that contained water and 
low penetration when applied in PG/LA (Table 2). 
 
 
Figure 2. Comparison of number of bases and steady state 
flux across hairless mouse skin for all oligomers tested in 
PG/LA (*, CTA; ■, TAG; ●, P53; ♦, MYB; ▼, MYC-1; ▲, 
MYC-2). Data reported as mean steady state ± S.E.
Figure 3. The proposed synergistic effect of vehicle combina-
tions on the skin permeation of the MYB oligomer. Theoret-
ical addition curve was determined by adding the mean of 
the two individual vehicle cumulative curves, at each time 
point (□, PG/LA; ∆, PG/LA:water; ▼, water; ♦, theoretical 
addition). S.E.M. for the theoretical curve was found by add-
ing the individual variances and then converting to S.E.M.
Table 2. Effect of vehicle composition on transport of oligomers
Oligo name               95% PG/        50% PG/LA/            25% PG/LA/                   100%                     Enhancement  
                                     5% LA              50% water                 75% water                      water                              ratioa
                           nb       SS fluxc          nb         SS fluxc             nb      SS fluxc            nb       SS fluxc            50/50     25/75    Water
TAG-6  8  6.6 ± 1.9  7  5.3 ± 2.0    5  2.0 ± 0.9  0.81   0.3
TAG-9-1  7  4.2 ± 1.1  6  2.6 ± 1.1    5  1.2 ± 0.3  0.62   0.27
TAG-12  10  3.3 ± 0.6  7  4.2 ± 1.6  3  1.4 ± 0.1  6  1.0 ± 0.3  1.29  1.36  0.32
CTA-6  6  24.1 ± 8.0  6  2.0 ± 0.4    7  0.4 ± 0.2  0.08   0.02
CTA-12  7  14.8 ± 5.5  7  8.1 ± 3.4  4  1.2 ± 0.3  8  0.2 ± 0.1  0.55  6.87  0.01
CTA-18  6  6.6 ± 1.6  5  7.4 ± 5.0    7  0.5 ± 0.3  1.13   0.07
CTA-24  5  4.7 ± 2.0  3  0.9 ± 0.7    6  0.4 ± 0.2  0.19   0.08
MYB  6  4.2 ± 1.0  4  15.3 ± 3.3    4  3.9 ± 0.8  3.68   0.93
MYC-1  5  11.3 ± 2.8  3  15.3 ± 6.3  3  5.1 ± 1.6  5  9.3 ± 4.3  1.38  0.54  0.84
MYC-2  7  10.7 ± 2.6  3  22.1 ± 4.4    5  14.3 ± 4.2  2.07   1.34
P53  6  2.3 ± 0.6  3  0.0 ± 0.0    6  0 ± 0.00  0   0
a. Mean steady state flux of each oligomer in a particular vehicle divided by its flux in 95% PG/5% LA.
b. Number of experimental replications for each vehicle combination.
c. Mean steady state flux in pmole/cm2 h from 5′M donor solution ± S.E.
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This flux data is supported by three sets of photo-
micrographs demonstrating that the majority of 
the compound remained on top of the stratum cor-
neum, with minimal localization within the skin 
when applied in water. In contrast, P53 applied in 
PG/LA showed penetration into the skin and accu-
mulation in the keratinocytes which would account 
for smaller than expected transdermal flux. The un-
treated control demonstrates that the fluorescence 
is due to the oligomer and not from the skin itself 
(Figure 4).
Examination of the penetration data revealed no 
correlation between flux and log octanol/water co-
efficient for any vehicle. PMOs with few guanines 
have their transdermal penetration inhibited in the 
presence of water (CTA and P53); however, the 
presence of G-quartets (MYB, MYC-1 and MYC-2) 
prevents this decrease in absorption.
4. Discussion
This work was designed to begin elucidating the 
relationship between PMO characteristics and ap-
propriate selection of chemical penetration enhanc-
ers. The data demonstrate that size, sequence, and 
thus base composition, will influence the transder-
mal flux of uncharged biologically active PMOs. 
Furthermore, modifying the concentration of the 
model penetration enhancer, propylene glycol, al-
tered the absorption of the PMOs through the skin 
in a sequence specific manner.
Several PMOs with biologically relevant tar-
gets were selected for these studies. Telomeres are 
stretches of a repeated sequence (5′-TTAGGG-3′) 
which form a cap at the end of the chromosome and 
are essential for chromosome protection and stabil-
ity. After each round of DNA replication the telo-
Figure 4. Comparison of the phase contrast and fluorescence photomicrographs of (a) control skin, (b) P53 oligomer delivered 
in PG/LA, (c) P53 oligomer delivered in a water vehicle. Note lack of fluorescence of control skin and that oligomer reaches 
keratinocytes when given in PG/LA, but remains on top of skin when applied in water (magnification 200×).
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meric portions of chromosomes are progressively 
shortened due to incomplete replication of 5′-ends of 
the linear DNA by the DNA polymerases. Telomer-
ase is an enzyme that can add 6-base repeats units 
of telomeric DNA to the 3′-ends of chromosomes, re-
placing the loss of telomeric DNA that occurs at each 
cell division. While telomerase is present in only 
a limited range of normal adult cells, studies have 
demonstrated that telomerase activity is activated in 
up to 90% of all human cancers, and may be impor-
tant in their immortalization (Urguidi et al., 1998). 
Inhibition of telomerase represents an ideal therapy 
against tumor growth. Since most normal cells lack 
this enzyme, it is an appealing target, in that, inhibi-
tion could cause minimal damage elsewhere in the 
patient. Previously, the ability of the phosphorothio-
ate TAG oligomers to specifically inhibit telomerase 
activity (Mata et al., 1997) and permeate the skin, us-
ing iontophoresis (Brand and Iversen, 1996; Brand et 
al., 1998a) has been demonstrated.
The other oligomers studied were antisense to 
some biologically relevant targets, including p53, c-
myb and c-myc. p53, a tumor suppressor gene, reg-
ulates the activity of several cell-cycle related genes 
and is important in cell proliferation. Mutations of 
this gene are found in more than half of all human 
cancers, including skin cancers, and the expression 
of p53 is up-regulated after ultraviolet radiation 
damage to DNA (Levine, 1997). The protooncogene 
c-myc is a transcriptional activator that plays a crit-
ical role in multiple pathways leading to the con-
trol of normal growth, cell cycle progression, cell 
proliferation, differentiation and apoptosis. It is ex-
pressed in nearly all replicating cells and expres-
sion is reduced after terminal differentiation. Eleva-
tion of this transcriptional activator and the DNA 
binding protein, c-myb, is associated with several 
pathologies, including restinosis and carcinogene-
sis (Nasi et al., 2001; Kipshidze et al., 2001).
Propylene glycol is one of the most widely used 
penetration enhancers in dermatological formula-
tions and has previously been shown to enable the 
absorption of topically applied PMOs completely 
through the skin (Arora et al., 2002). It can however 
lead to skin irritation at concentrations greater than 
50% (v/v) (Lashmar et al., 1989). The ability of ve-
hicles consisting of lower concentrations of propyl-
ene glycol to enhance the permeation of oligomers 
was therefore investigated. Propylene glycol func-
tions as a cosolvent, by accumulating in the stratum 
corneum, thereby changing its solubility character-
istics. It acts synergistically to increase partitioning 
of candidate molecules and other enhancers such as 
fatty acids into the stratum corneum, thus signifi-
cantly increasing the activity of co-enhancers (Wal-
ters, 1989; Barry, 1991; Hadgraft et al., 1992; Asbill 
et al., 2000). Fatty acids, such as linoleic acid, serve 
as penetration enhancers by disrupting ceramide–
cholesterol and or cholesterol–cholesterol ordered 
structures in the stratum corneum, leading to in-
crease drug permeation (Asbill et al., 2000).
The transport of the PMOs mimicking both the 
telomeres (TAG oligomers) and their complements 
(CTA oligomers) was examined in order to isolate 
the effect of either size or sequence on transdermal 
absorption. For both the TAG and CTA oligomers, 
transport across the skin was inversely related to 
their size when applied in a PG/LA formulation. 
This would be expected based on the “rules” gov-
erning transdermal drug delivery (Kasting et al., 
1987). In a similar study (Brand et al., 1998a) using 
iontophoretic delivery of phosophorothioate oligo-
mers with the TAG and CTA sequences, the gen-
eral inverse trend between size and flux was seen, 
but the linearity was not as clear as for the PG/LA 
studies presented in this work. A similar relation-
ship between size and flux was also identified for 
passively delivered methylphosphanate oligomers 
(Nolen et al., 1994) and iontophoretically deliv-
ered phosphodiester oligomers with equal portions 
of each base (Oldenberg et al., 1995). However, 
the effects of size and sequences, as well as oligo-
mer chemistry and penetration techniques, can-
not be separated in these previous studies. Interest-
ingly, the size-flux trend was not evident for either 
the TAG or CTA sequences when the vehicle was 
changed to 50% PG/LA:50% water or 100% water.
The power of synthesizing two series of oligo-
mers (TAG and CTA) with increasing sequence 
length is that it enables the separation of the effects 
of size versus sequence on transdermal penetra-
tion for the PMOs. This approach is similar to stud-
ies examining the percutaneous absorption of the 
alkanols ranging from methanol to nonanol (Dur-
rheim et al., 1980). While size was linearly related to 
transdermal transport for the TAG and CTA mole-
cules, there are obvious differences in penetration 
due to sequence.
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Examining the other oligomers in this study re-
veals some diverse effects of size on transdermal 
permeation. The MYB oligomer exhibited flux sim-
ilar to what would be expected in terms of its size, 
given that its transport was equal to that of CTA-
24. The P53 oligomer, which was the same size as 
the MYC oligomers, exhibited substantially lower 
flux. The explanation for this P53 observation, how-
ever, was provided by examining the fluorescent 
photographs that demonstrated its extensive local-
ization within the keratinocytes when delivered in 
the PG/LA vehicle.
As oligomers cross the skin, the first viable cells 
they encounter are the keratinocytes. Keratino-
cytes are very responsive to oligomers, because 
they can internalize these molecules rapidly, with-
out cell surface accumulation or endosomal seques-
tration (Noonberg et al., 1993; Nestle et al., 1994). 
The MYC-1 and P53 results are consistent with ear-
lier studies that correlated the delivery of PSOs 
across hairless mouse skin with their uptake by ke-
ratinocytes (Brand et al., 1998b). They found that a 
PS MYC oligomer, with the same sequence as the 
PMO MYC-1 studied here, had almost no kerati-
nocyte uptake but had very high transport across 
the skin, consistent with the transport of the MYC-
1 oligomer in this study. Additionally the PS P53 
oligomer, again with the same sequence as the one 
in this study, had very high uptake by keratino-
cytes, with low transport across the skin, identical 
to the findings in this paper.
While molecular size can impact transdermal de-
livery, lipophilicity is actually considered more im-
portant than size in predicting the transdermal pen-
etration of small molecules (Potts and Guy, 1992). 
Two different sequences (MYC-1, MYC-2) were 
synthesized, targeted to inhibit expression of the 
c-myc gene. We hypothesized that these oligomers 
would have different penetration levels because 
their lipophilicities differ by a factor of four. These 
oligomers both had a higher flux than would be ex-
pected based on their size, but similar flux to each 
other, indicating that lipophilicity does not seem to 
play a role in their absorption.
The different transdermal delivery potential of 
the TAG and CTA molecules may be explained by 
the large number of guanines present in the TAG 
oligomers. These bases may cause the oligomers to 
fold into structures that are not easily transported 
through the skin (Smith and Feigon, 1993). Stud-
ies on iontophoretic transport of the TAG-9 PSO re-
vealed that subtle changes in molecular structure 
can have a significant impact on the percutaneous 
penetration of oligomers. Modifying the center of 
the molecules reduced polarity and steric-hindrance 
while the mass/charge ratio increased, resulting in 
greater penetration (unpublished results). Further-
more, comparing the iontophoretic transdermal pen-
etration of a 15-base thrombin aptamer consisting 
of nine guanines and six thymidines with a globu-
lar three-dimensional (3D) structure to a scrambled 
aptamer without a similar 3D structure revealed that 
the active compound had two-fold lower penetra-
tion than the scrambled sequence, again demonstrat-
ing the influence of structure on transdermal deliv-
ery (Oldenberg et al., 1995). The effects of guanines 
on dermal penetration can also be seen when water 
is used as a solvent. Flux was significantly inhibited 
in those sequences that contained low levels of gua-
nine residues (CTA & P53), was not effected at all for 
those PMOs containing a G-quartet (MYC-1, MYC-2 
and MYB) and was partially inhibited for the PMOs 
with only three G’s in a row (TAG).
Comparing the transport of all oligomers in 
this study with that achieved by their counterpart 
phosphorothioate oligomers delivered with ion-
tophoresis indicates the TAG molecules, deliv-
ered in any vehicle, can achieve permeation simi-
lar to that achieved with iontophoresis (Brand et 
al., 1998a). MYC-1 and MYC-2 oligomer transport 
in all vehicles was nearly the same as that achieved 
with iontophoresis, with MYC-2’s transport in the 
50% propylene glycol (with linoleic acid)/50% wa-
ter vehicle exceeding that achieved with iontopho-
resis. Finally, MYB transport was higher in all vehi-
cles in this study (water, 50% water/50% PG/LA, 
and PG/LA) than with iontophoresis, with trans-
port in the 50% water/50% PG/LA being over 10 
times that achieved with iontophoresis.
In summary, for sequences targeted to the en-
zyme telomerase, flux is related inversely to size, 
supporting previous studies which report simi-
lar results for other oligomer chemistries (Nolen et 
al., 1994; Brand et al., 1998a; Oldenberg et al., 1995). 
Additionally, differential transport of equivalently 
sized oligomers of varying sequence suggests that 
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oligomer permeation is sequence specific. While se-
quence and size can be used to explain most trans-
port, the MYC and P53 oligomers reveal that the 
target for these antisense molecules may also play a 
role in determining the ability of these compounds 
to cross the skin with some oligomers (TAG-6) be-
ing better for transdermal delivery and others (P53) 
for topical applications. Furthermore, the PMO se-
quence will influence the selection of an optimal 
penetration enhancer with those containing G-
quartets having good transport in a water contain-
ing solvent. This study also has demonstrated that 
PMOs can achieve passive transport across skin 
that meets or surpasses that of iontophoretically 
delivered PSOs of equivalent sequence.
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